Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CureVac gets first mRNA vaccine data in humans; waits for next step

This article was originally published in Scrip

Executive Summary

CureVac, a small mRNA vaccine company in Tuebingen, Germany has shown that its CV9301 product for hormone-refractory prostate cancer is safe, well-tolerated and can elicit both a cellular and humoral immune response in a a high percentage of trial subjects. The data, from an open lable Phase I/IIa trial, announced on 4 October, are the company's first clinical results but the company now plans to wait for further results from an ongoing Phase I trial of a second product, CV9201 in non-small cell lung cancer before finalising its development strategy. "What is clear is that we don't stop here," said CEO Mr Ingmar Hoerr. "But how the product goes forward is unclear." The company will follow the prostate cancer patient outcomes for a year and then decide on its strategy. He explained that CureVac saw the results on CV9103 as the proof of concept that mRNA-based vaccines can stimulate a human immune response against a range of antigens.

You may also be interested in...

Gender Diversity In Pharma: Caught Between Desire And Reality

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Women In High Places: Slow Progress In Pharma

With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.

Stock Scan April 2018: Pharma's Fizz Falls Flat

In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts